Last reviewed 2026-04-22 · How we verify

LAIS®

Ajou University School of Medicine · FDA-approved active Small molecule

LAIS® is a Intracameral corticosteroid implant Small molecule drug developed by Ajou University School of Medicine. It is currently FDA-approved for Post-operative inflammation following cataract surgery, Anterior uveitis. Also known as: active treatment.

LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation.

LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation. Used for Post-operative inflammation following cataract surgery, Anterior uveitis.

At a glance

Generic name	LAIS®
Also known as	active treatment
Sponsor	Ajou University School of Medicine
Drug class	Intracameral corticosteroid implant
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

LAIS (Levotas Aqueous Implant System) is a biodegradable intracameral implant designed to provide prolonged corticosteroid delivery to the anterior segment of the eye. By releasing dexamethasone directly into the aqueous humor over an extended period, it maintains therapeutic anti-inflammatory levels while minimizing systemic exposure and the need for frequent topical dosing.

Approved indications

Post-operative inflammation following cataract surgery
Anterior uveitis

Common side effects

Elevated intraocular pressure
Cataract progression
Corneal edema

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LAIS® CI brief — competitive landscape report
LAIS® updates RSS · CI watch RSS
Ajou University School of Medicine portfolio CI

Frequently asked questions about LAIS®

What is LAIS®?

LAIS® is a Intracameral corticosteroid implant drug developed by Ajou University School of Medicine, indicated for Post-operative inflammation following cataract surgery, Anterior uveitis.

How does LAIS® work?

LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation.

What is LAIS® used for?

LAIS® is indicated for Post-operative inflammation following cataract surgery, Anterior uveitis.

Who makes LAIS®?

LAIS® is developed and marketed by Ajou University School of Medicine (see full Ajou University School of Medicine pipeline at /company/ajou-university-school-of-medicine).

Is LAIS® also known as anything else?

LAIS® is also known as active treatment.

What drug class is LAIS® in?

LAIS® belongs to the Intracameral corticosteroid implant class. See all Intracameral corticosteroid implant drugs at /class/intracameral-corticosteroid-implant.

What development phase is LAIS® in?

LAIS® is FDA-approved (marketed).

What are the side effects of LAIS®?

Common side effects of LAIS® include Elevated intraocular pressure, Cataract progression, Corneal edema.

What does LAIS® target?

LAIS® targets Glucocorticoid receptor and is a Intracameral corticosteroid implant.

Drug class: All Intracameral corticosteroid implant drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Ajou University School of Medicine — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Post-operative inflammation following cataract surgery
Indication: Drugs for Anterior uveitis
Also known as: active treatment

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing